brexucabtagene autoleucel
gilead sciences
['tecartus', 'cart,(-cartitude)', 'leusm', 'zuma-3']
#asco22 #leusm leonard: 2yr followup of zuma-3 study with kte-x19 (tecartus). median dor 14.6 mos in those achieving cr/cri, 20min in true cr (linger when not censored for allohct [18.6/20.8mos] suggesting allo may play a role in longer dor, but not yet clear). 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)